PRESS RELEASE published on 05/05/2025 at 09:05, 8 months 30 days ago BioNxt Solutions Reports Expanded Patent Protection from the Eurasian Patent Organization BioNxt Solutions Inc. announces acceptance of its first national level patent filing by Eurasian Patent Organization, covering sublingual drug delivery for neurodegenerative diseases BioNxt Solutions Inc. Patent Filing Neurodegenerative Diseases Sublingual Delivery Eurasian Patent Organization
BRIEF published on 05/02/2025 at 01:55, 9 months 3 days ago BioNxt Solutions Delays 2024 Annual Financial Statement Filing Management Cease Trade Order Healthcare Innovation Financial Statements Delay Annual Filings BioNxt Solutions
BRIEF published on 05/02/2025 at 01:55, 9 months 3 days ago BioNxt Solutions retarde le dépôt de ses états financiers annuels pour 2024 Dépôts Annuels Solutions BioNxt Retard Des États Financiers Innovation Dans Le Domaine Des Soins De Santé Ordonnance De Cessation D'opérations De La Direction
PRESS RELEASE published on 05/02/2025 at 01:50, 9 months 3 days ago BioNxt Solutions Announces Delay In Filing 2024 Annual Financial Statements BioNxt Solutions Inc. announces delay in filing annual financial statements for year ended December 31, 2024. Company working on completing filings by June 28, 2025, under management cease trade order Financial Statements Management Cease Trade Order BioNxt Solutions Inc. Delay Regulatory Authorities
BRIEF published on 04/23/2025 at 09:10, 9 months 11 days ago BioNxt Solutions Advances in MS Treatment Study Multiple Sclerosis Cladribine Drug Delivery Innovation BioNxt Solutions Bioequivalence Study
BRIEF published on 04/23/2025 at 09:10, 9 months 11 days ago BioNxt Solutions progresse dans une étude sur le traitement de la sclérose en plaques Sclérose En Plaques Cladribine Solutions BioNxt Étude De Bioéquivalence Innovation En Matière D'administration De Médicaments
PRESS RELEASE published on 04/23/2025 at 09:05, 9 months 11 days ago BioNxt Solutions Prepares for Human Bioequivalence Study For MS BioNxt Solutions Inc. reports advanced preparation for human bioequivalence study of BNT23001, a novel sublingual thin-film Cladribine formulation for Multiple Sclerosis treatment BioNxt Solutions Inc. Multiple Sclerosis Treatment Sublingual Thin-Film BNT23001 Human Bioequivalence Study
BRIEF published on 03/15/2025 at 00:05, 10 months 21 days ago BioNxt Solutions Closes Final Tranche of Convertible Debenture Offering Private Placement Convertible Debenture Warrants Financing BioNxt Solutions
BRIEF published on 03/15/2025 at 00:05, 10 months 21 days ago BioNxt Solutions clôture la dernière tranche de son offre d'obligations convertibles Financement Placement Privé Mandats Obligation Convertible Solutions BioNxt
PRESS RELEASE published on 03/15/2025 at 00:00, 10 months 21 days ago BioNxt Solutions Announces Closing of Final Tranche of Fully Subscribed Convertible Debenture Unit Private Placement BioNxt Solutions Inc. completes final tranche of convertible debenture Offering for $900,000. Funds to be used for product dev, IP, debt repayment, and working capital Private Placement Convertible Debenture Healthcare BioNxt Solutions Inc. Drug Delivery Technologies
Published on 02/05/2026 at 01:35, 5 hours 44 minutes ago Dr. Ruben Shiffman Files Early Warning Report in Respect of Greenland Resources
Published on 02/05/2026 at 00:00, 7 hours 19 minutes ago Onco-Innovations Announces Filing of Preliminary Base Shelf Prospectus
Published on 02/04/2026 at 22:25, 8 hours 54 minutes ago 55 North Mining Announces Flow-Through Financing
Published on 02/04/2026 at 16:15, 15 hours 4 minutes ago Trans Canada Gold Enters into an Option Agreement with Bear Mountain Gold Mines to Acquire a 60% Interest in the Harrison Lake District Scale Gold Property, with $10.0 Million Dollars in Prior Exploration Expenditures
Published on 02/05/2026 at 07:00, 18 minutes ago Aurubis AG: Aurubis achieves quarterly result in line with market expectations and upgrades 2025/26 forecast
Published on 02/05/2026 at 07:00, 18 minutes ago FY2025: Resilient rental income and record new money in Asset Management ensure stable FFO I of CHF 4.22 per share; higher dividend of CHF 3.50 per share proposed
Published on 02/05/2026 at 07:00, 18 minutes ago Rational AG reports growth of 8 percent after exchange rate adjustments – preliminary figures for the 2025 fiscal year
Published on 02/05/2026 at 07:00, 18 minutes ago CGTN: Vision 2030: China's tech blueprint reshaping global innovation
Published on 02/05/2026 at 07:00, 19 minutes ago SIG Group: New CEO Mikko Keto to start on 1 March 2026
Published on 02/04/2026 at 18:04, 13 hours 15 minutes ago Capital et droits de vote au 31 janvier 2026
Published on 02/04/2026 at 18:04, 13 hours 15 minutes ago Total number of voting rights and shares making up the share capital at January 31, 2026
Published on 02/04/2026 at 17:45, 13 hours 34 minutes ago Information concerning the total number of voting rights and shares 2026 01 31
Published on 02/04/2026 at 17:45, 13 hours 34 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
